Anders Stahlberg
Overview
Explore the profile of Anders Stahlberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
137
Citations
4231
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xia Y, Caputo M, Andersson E, Asiedu B, Zhang J, Hou W, et al.
Cell Mol Gastroenterol Hepatol
. 2025 Mar;
:101485.
PMID: 40024534
Background & Aims: Hepatocellular carcinoma (HCC) is a rapidly growing malignancy with high mortality. Recently, metabolic dysfunction-associated steatohepatitis (MASH) has emerged as a major HCC catalyst; however, signals driving transition...
2.
Micallef P, Santamaria M, Escobar M, Andersson D, Osterlund T, Mouhanna P, et al.
Genome Biol
. 2025 Feb;
26(1):37.
PMID: 40001095
Digital sequencing uses unique molecular identifiers (UMIs) to correct for polymerase induced errors and amplification biases. Here, we design 19 different structured UMIs to minimize the capacity of primers to...
3.
Mouhanna P, Stahlberg A, Andersson D, Albu-Kareem A, Elinder E, Eriksson O, et al.
Int J Cancer
. 2024 Dec;
156(8):1509-1517.
PMID: 39692755
Circulating tumour DNA (ctDNA) is an emerging biomarker for monitoring cancers. The personalised disease monitoring in metastatic breast cancer (PDM-MBC) study is an ongoing study instigated to evaluate ctDNA as...
4.
Rahmqvist I, Engstrom E, Mellstrom E, Ibrahim R, Pujol-Calderon F, Dahlstrand Rudin A, et al.
Biomark Res
. 2024 Nov;
12(1):148.
PMID: 39593169
Circulating tumor DNA (ctDNA) has shown potential as a non-invasive tumor biomarker in neuroblastoma. Previous studies used generic assays for detection of selected predefined oncogenic variants as markers of ctDNA,...
5.
Elliott K, Singh V, Backerholm A, Ogren L, Lindberg M, Soczek K, et al.
Nat Commun
. 2024 Nov;
15(1):9965.
PMID: 39557834
Non-coding mutations in the TERT promoter (TERTp), typically at one of two bases -124 and -146 bp upstream of the start codon, are among the most prevalent driver mutations in...
6.
Rahimi S, Balusamy S, Perumalsamy H, Stahlberg A, Mijakovic I
Nucleic Acids Res
. 2024 Aug;
52(17):10040-10067.
PMID: 39189452
Nucleic acid-based diagnostics is a promising venue for detection of pathogens causing infectious diseases and mutations related to cancer. However, this type of diagnostics still faces certain challenges, and there...
7.
Ek T, Ibrahim R, Vogt H, Georgantzi K, Trager C, Gaarder J, et al.
Cancer Res Commun
. 2024 Aug;
4(9):2553-2564.
PMID: 39177282
Significance: We present five patients with ALK-driven relapsed or refractory neuroblastoma treated with lorlatinib as monotherapy. All patients responded to treatment, and four of them were alive after 3 to...
8.
Rodin W, Szeponik L, Rangelova T, Tamiru Kebede F, Osterlund T, Sundstrom P, et al.
Cancer Immunol Immunother
. 2024 Jul;
73(9):174.
PMID: 38953978
Γδ T cell infiltration into tumours usually correlates with improved patient outcome, but both tumour-promoting and tumoricidal effects of γδ T cells have been documented. Human γδ T cells can...
9.
Kubista M, Andersson D, Stahlberg A
Mol Aspects Med
. 2024 May;
98:101278.
PMID: 38777730
No abstract available.
10.
Ranji P, Jonasson E, Andersson L, Filges S, Santamaria M, Vannas C, et al.
J Transl Med
. 2024 Apr;
22(1):389.
PMID: 38671504
Background: Myxoid liposarcoma (MLS) displays a distinctive tumor microenvironment and is characterized by the FUS::DDIT3 fusion oncogene, however, the precise functional contributions of these two elements remain enigmatic in tumor...